title: Effects of rapamycin on the epithelial-to-mesenchymal transition of human peritoneal mesothelial cells.
abstract: The preservation of the peritoneal membrane is crucial for long-term survival in peritoneal dialysis. Epithelial-to-mesenchymal transition (EMT) is a process demonstrated in mesothelial cells (MC), responsible for negative peritoneal changes and directly related to PD. EMT enables neovascularization and fibrogenic capabilities in MC. Vascular endothelial growth factor (VEGF) is the mediator for neo-vascularization. Rapamycin is a potent immunosuppressor with antifibrotic action in renal allografts and has a demonstrated anti-VEGF effect. We performed this study with the hypothesis that rapamycin may regulate the EMT of MC. MC from human omentum were cultured. When mesothelial cells reached confluence, some of them were stimulated with r-TGF-beta (1 ng/mL) to induce EMT, co-administered with rapamycin (0.2, 2, 4, 20 and 40 nM). Other groups of cells received similar doses of rapamycin or r-TGF-beta, separately. Cells were analyzed at 6, 24, 48 hours and 7 days. As markers of EMT we included alfa -SMA, E-cadherin and snail nuclear factor by quantitative RT-PCR. EMT markers and regulators demonstrated the following changes with rapamycin: E-cadherin (a protective gene for EMT) increased 2.5-fold relative to controls under 40 nM, at 24h. Importantly, rapamycin inhibited snail expression induced by TGF-beta at 6h, whereas TGF-beta increased snail 10-fold. At day 7, rapamycin showed no anti-EMT properties. An important decrease in alfa -SMA expression by MC after rapamycin addition was observed. In conclusion, rapamycin shows a mild protective effect on EMT, as it increases E-cadherin and decreases alfa -SMA expression. Consequently, rapamycin might partially regulate the epithelial-to-mesenchymal transition of mesothelial cells.
authors.affiliation: Department of Nephrology, University Hospital La Princesa, 28006 Madrid, Spain. aguileraa@terra.es
authors.forename: A
authors.initials: A
authors.lastname: Aguilera
authors.forename: L S
authors.initials: LS
authors.lastname: Aroeira
authors.forename: M
authors.initials: M
authors.lastname: Ramirez-Huesca
authors.forename: M L
authors.initials: ML
authors.lastname: Perez-Lozano
authors.forename: A
authors.initials: A
authors.lastname: Cirugeda
authors.forename: M A
authors.initials: MA
authors.lastname: Bajo
authors.forename: G
authors.initials: G
authors.lastname: Del Peso
authors.forename: A
authors.initials: A
authors.lastname: Valenzuela-Fernandez
authors.forename: J A
authors.initials: JA
authors.lastname: Sanchez-Tomero
authors.forename: M
authors.initials: M
authors.lastname: Lopez-Cabrera
authors.forename: R
authors.initials: R
authors.lastname: Selgas
mesh_terms: D000199:Actins / Q000378:metabolism; D015415:Biomarkers / Q000378:metabolism; D015153:Blotting, Western; D015820:Cadherins / Q000378:metabolism; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004847:Epithelial Cells / Q000187:drug effects* / Q000378:metabolism*; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D066298:In Vitro Techniques; D009852:Omentum / Q000166:cytology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D020123:Sirolimus / Q000494:pharmacology*; D016212:Transforming Growth Factor beta / Q000494:pharmacology
chemical_list: D000199:Actins; D015415:Biomarkers; D015820:Cadherins; D007166:Immunosuppressive Agents; D016212:Transforming Growth Factor beta; D020123:Sirolimus